3236 Periodontal therapy and diabetes glycemic control
S.G. GROSSI1, F. SKREPCINSKI2, A. HO1, S. GARRETT3, W. ORTOLANO3, and R.J. GENCO1, 1SUNY at Buffalo, NY, USA, 2Indian Health Service, Albuquerque, NM, USA, 3Atrix Laboratories, Fort Collins, CO, USA

Objective: To examine the effect of periodontal treatment on long-term glycemic control of diabetes. Methods: 75 Pueblo Indians with type 2 diabetes and severe periodontal disease were included in this randomized trial. Patients received ultrasonic debridement under continuous irrigation with 0.12% Chlorhexidine and one of the following regimes: a) single oral doxycycline 100 mg/bid, b) multiple oral doxycycline 100 mg/bid (baseline and 6 months); c) single oral doxycycline 100 mg/bid and multiple topical doxycycline (Atridox) every 3 months; d) multiple oral doxycycline 100 mg/bid and topical Atridox. Periodontal status and diabetes control were assessed at 3, 6, 9 and 12 months. Results: All 4 groups showed a significant reduction in percent sites with PD > 5 mm (P< 0.01) ranging from 17% to 27%. Patients with baseline > 9% glycated hemoglobin (HbA1c), i.e., uncontrolled diabetes, showed a reduction in this parameter ranging from 0.5 to 1.7% (P< 0.05). The greatest reduction in HbA1c levels was seen in the single oral doxycycline and multiple Atridox group. Levels of HbA1c in this group were reduced 1.1% at 1 month and 1.7% at 12 months (P< 0.01). A multiple regression model revealed that for every mm increment in mean pocket depth following periodontal therapy, HbA1c increased by 0.3 %, independent of the effect of age, gender and baseline level of HbA1c or pocket depth (P< 0.001). Our results demonstrate a significant reduction in levels of HbA1c in patients with uncontrolled diabetes following antiinfective periodontal therapy and that this reduction can be sustained for 12 months. Conclusions: Ultrasonic debridement combined with oral doxycycline and repeated topical doxycycline results in a long term reduction in levels of glycated hemoglobin. Therefore, regular antiinfective periodontal therapy in diabetics with periodontal disease is important for long-term glycemic control. Supported by DHHS Grant No. 282980004 and Atrix Laboratories.

Seq #300 - Emerging Concepts - Periodontal Epidemiology and Diagnosis
9:00 AM-11:00 AM, Saturday, 9 March 2002 San Diego Convention Center Room 6E (Upper level)

Back to the Periodontal Research - Therapy Program
Back to the IADR/AADR/CADR 80th General Session (March 6-9, 2002)

Top Level Search